Journals / İzmir Atatürk Eğitim Hastanesi Tıp Dergisi / 2008 / Cilt: 46 - Sayı: 2

The evaluation of HBV DNA serologic markers and transaminase levels in occult hepatitis B infection

HBV DNA, serolojik göstergeler ve transaminaz düzeylerinin okült hepatit B infeksiyonu yönünden değerlendirilmesi

Pages
77–79
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results suggested that HBV DNA levels may be very useful in diagnosis and follow-up periods of HBV infection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aimed to evaluation HBV DNA levels, HBsAg positivity and transaminase levels for occult hepatitis in patients with HBV infection.
📊
Key Findings & Data:Serum HBV DNA levels of 122 patients were studied by b- DNA (versant 3.0, Bayer).
💡
Conclusion & Impact:Our results suggested that HBV DNA levels may be very useful in diagnosis and follow-up periods of HBV infection.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

We aimed to evaluation HBV DNA levels, HBsAg positivity and transaminase levels for occult hepatitis in patients with HBV infection. Serum HBV DNA levels of 122 patients were studied by b- DNA (versant 3.0, Bayer). Serological markers were determined by chemilimunescence method (VITROS,Ortho-clinical diagnostics). Results were evaluated with transaminase levels by retrospectively. HBsAg was found negative in four (3.27 %) of patient. It was detected antiHBc positivity in three of patient and anti HCV positivity in one of patient. HBV DNA levels were 2000< genome/ml of patients. Our results suggested that HBV DNA levels may be very useful in diagnosis and follow-up periods of HBV infection. Serologic markers, HBV DNA and transaminase should be evaluated in ocult hepatitis infections.

Özet

Hepatit B virus (HBV) infeksiyonlu hastalarda serum HBV DNA miktarları, HBsAg ve transaminaz düzeylerinin okült hepatit yönünden değerlendirilmesi. Bu çalışmada 122 HBV ile enfekte hastanın serum örneklerinde HBV DNA, b- DNA (versant 3.0, Bayer) testi ile çalışıldı. Serolojik göstergeler, kemilüminesans yöntemi (VITROS, Ortho - clinical diagnostics) ile çalışıldı. Sonuçlar transaminaz düzeyleri ile retrospektif olarak değerlendirildi. Hastaların dördünde (% 3.27) HBsAg negatif bulundu. Üç hastada antiHBc, bir hastada antiHCV pozitifliği saptandı. HBV DNA düzeyleri 2000< genom/ml idi. Hastalardan elde edilen HBV DNA düzeyleri tanı ve izlemde yararlıdır. Okült hepatit tablosunda; serolojik göstergeler, HBV DNA ve transaminazlar birlikte değerlendirilmelidir.

🔖

Cite This Article

YURTSEVER, S. G., KURULTAY, N., TÜRKER, M., AFŞAR, İ., ŞENER, A. G. (2022). The evaluation of HBV DNA serologic markers and transaminase levels in occult hepatitis B infection. İzmir Atatürk Eğitim Hastanesi Tıp Dergisi, Cilt: 46 - Sayı: 2, 77–79. https://ajindex.com/articles/557522

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Torbenson M, Thomas DL. Occult hepatitis B. LancetInfect Dis 2002; 2: 479-486
  2. Thiers V, Nakajima E, Kremsdorf D, et al. Transmission of hepatitis B from hepatitis B seronegative subjects. Lancet 1988; 2: 1273
  3. Marusava H, Uemoto S, Hijikata M, et al. Latent hepatitis B virus infection in healthy individual with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495
  4. Fukuda R, Ishimura N, Niigaki M, et al.Serologically silent hepatitis B virus coinfection in patient with hepatitis C virus associated chronic liver disease: clinical and virological significance. J Med Virol 1999; 58: 201-207
  5. Cacciola I, Pollicino T, Squadrito G, et al. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology 2000; 31: 507-512
  6. Nirei K, Kaneko M, Arakawa Y. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology 2000; 43: 95-101
  7. Khan MH, Farrel GC, Byth K, et al. Which patients with hepatitis C develop liver complication? Hepatology 2000; 31: 513-520
  8. Kao JH, Chen PJ, Lai MY, Chen DS. Occult HBV infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40(11): 4068-4071
  9. Zigneno AL, Fontana R, Puliti S, et al. Relevance of inapparent co-infection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51: 313-318
  10. Zhang YY, Hansson BG, Kuo LS, Widel A, Nordenfelt E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 1993; 17: 538-544
  11. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and ‘’silent’’ HBV coinfection:Two main risk factors for a more severe liver disease. J Med Virol 2001; 64: 350-355
  12. Maria ND, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. The American Journal of Gastroenterology 2000; 95: 3529-3536
  13. Chaudhuri V, Saxena A, Hazari S, Acharya S, Panda SK. Hepatitis B virus seronegative samples. Antiviral Ther 2000; 5: B21
  14. Yalçın K, Değertekin H, Yıldız F, Çelik Y. Markers of disease activity in chronic hepatitis B virus. Clin Invest Med 2003; 26(1): 27-34
  15. Zeren İ, Eyigün CP, Güner ÖR, Pahsa A. Transaminazları normal olan kr